Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Lance Smith

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Callithrix

Chemicals & Drugs

Activities & Behaviors

Disorders

Concepts & Ideas

Drug Dose-Response Relationship

Anatomy

Substantia Nigra

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
27
Jenner, Peter
17
Jackson, Michael
7
Rose, Sarah
6
Pearce, R K B
6
Marsden, CD
4
Al-Barghouthy, Ghassan
4
Gnanalingham, Kanna
3
iravani, mahmoud
3
Tel, Banu
3
Cheetham, Sharon
3
Hansard, Matthew
3
Kanda, T
3
Kase, Hiroshi
3
Kuwana, Yoshihisa
2
Lange, Klaus

Sign-in to see all Coauthors

Publications

TOP 3
Stockwell K A; Scheller D; Rose S; Jackson M J; Tayarani-Binazir K; Iravani M M; Smith L A; Olanow C W; Jenner P
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Zubair Mohammed; Jackson Michael J; Tayarani-Binazir Kayhan; Stockwell Kim A; Smith Lance A; Rose Sarah; Olanow Warren; Jenner Peter
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Kuoppamäki M; Al-Barghouthy G; Jackson M J; Smith L A; Quinn N; Jenner P
L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Lance Smith (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Stockwell K A; Scheller D; Rose S; Jackson M J; Tayarani-Binazir K; Iravani M M; Smith L A; Olanow C W; Jenner P
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Experimental neurology 2009;219(2):533-42.
2007: Zubair Mohammed; Jackson Michael J; Tayarani-Binazir Kayhan; Stockwell Kim A; Smith Lance A; Rose Sarah; Olanow Warren; Jenner Peter
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Experimental neurology 2007;208(2):177-84.
2007: Kuoppamäki M; Al-Barghouthy G; Jackson M J; Smith L A; Quinn N; Jenner P
L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates.
Journal of neural transmission (Vienna, Austria : 1996) 2007;114(9):1147-53.
2007: Jackson Michael J; Smith Lance A; Al-Barghouthy Ghassan; Rose Sarah; Jenner Peter
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
Experimental neurology 2007;204(1):162-70.
2006: Iczkiewicz Joanna; Jackson Michael J; Smith Lance A; Rose Sarah; Jenner Peter
Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease.
Brain research 2006;1118(1):239-50.
2006: Smith Lance A; Jackson Michael J; Johnston Louisa; Kuoppamaki Mikko; Rose Sarah; Al-Barghouthy Ghassan; Del Signore Susanna; Jenner Peter
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
Clinical neuropharmacology 2006;29(3):112-25.
2005: Smith Lance A; Jackson Michael J; Al-Barghouthy Ghassan; Rose Sarah; Kuoppamaki Mikko; Olanow Warren; Jenner Peter
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Movement disorders : official journal of the Movement Disorder Society 2005;20(3):306-14.
2005: Iravani Mahmoud M; Syed Emilie; Jackson Michael J; Johnston Louisa C; Smith Lance A; Jenner Peter
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
The European journal of neuroscience 2005;21(4):841-54.
2004: Hansard Matthew J; Smith Lance A; Jackson Michael J; Cheetham Sharon C; Jenner Peter
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Movement disorders : official journal of the Movement Disorder Society 2004;19(1):15-21.
2004: Zeng B-Y; Smith L A; Pearce R K B; Tel B; Chancharme L; Moachon G; Jenner P
Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of MPTP-treated common marmosets.
Neuroscience letters 2004;354(1):6-9.
2003: Iravani Mahmoud M; Jackson Michael J; Kuoppamäki Mikko; Smith Lance A; Jenner Peter
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2003;23(27):9107-15.
2002: Hansard Matthew J; Smith Lance A; Jackson Michael J; Cheetham Sharon C; Jenner Peter
Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
The Journal of pharmacology and experimental therapeutics 2002;303(3):952-8.
2002: Smith Lance A; Tel Banu C; Jackson Michael J; Hansard Matthew J; Braceras Rogelio; Bonhomme Céline; Chezaubernard Claire; Del Signore Susanna; Rose Sarah; Jenner Peter
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
Movement disorders : official journal of the Movement Disorder Society 2002;17(5):887-901.
2002: Hansard Matthew J; Smith Lance A; Jackson Michael J; Cheetham Sharon C; Jenner Peter
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.
European journal of pharmacology 2002;451(2):157-60.
2002: Smith L A; Jackson M J; Al-Barghouthy G; Jenner P
The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration.
Journal of neural transmission (Vienna, Austria : 1996) 2002;109(2):123-40.
2000: Treseder S A; Smith L A; Jenner P
Endogenous dopaminergic tone and dopamine agonist action.
Movement disorders : official journal of the Movement Disorder Society 2000;15(5):804-12.
2000: Jenner P; Zeng B Y; Smith L A; Pearce R K; Tel B; Chancharme L; Moachon G
Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 2000;133(2):178-88.
2000: Smith L A; Jackson M G; Bonhomme C; Chezaubernard C; Pearce R K; Jenner P
Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset.
Clinical neuropharmacology 2000;23(3):133-42.
2000: Kanda T; Jackson M J; Smith L A; Pearce R K; Nakamura J; Kase H; Kuwana Y; Jenner P
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Experimental neurology 2000;162(2):321-7.
1999: Kuwana Y; Shiozaki S; Kanda T; Kurokawa M; Koga K; Ochi M; Ikeda K; Kase H; Jackson M J; Smith L A; Pearce R K; Jenner P G
Antiparkinsonian activity of adenosine A2A antagonists in experimental models.
Advances in neurology 1999;80():121-3.
1998: Kanda T; Jackson M J; Smith L A; Pearce R K; Nakamura J; Kase H; Kuwana Y; Jenner P
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
Annals of neurology 1998;43(4):507-13.
1995: Gnanalingham K K; Milkowski N A; Smith L A; Hunter A J; Jenner P; Marsden C D
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
European journal of pharmacology 1995;277(2-3):235-41.
1995: Gnanalingham K K; Erol D D; Hunter A J; Smith L A; Jenner P; Marsden C D
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Psychopharmacology 1995;117(3):275-86.
1995: Gnanalingham K K; Milkowski N A; Smith L A; Hunter A J; Jenner P; Marsden C D
Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity.
Journal of neural transmission. General section 1995;101(1-3):65-82.
1993: Gnanalingham K K; Smith L A; Hunter A J; Jenner P; Marsden C D
Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Synapse (New York, N.Y.) 1993;14(2):184-94.
1992: Löschmann P A; Smith L A; Lange K W; Jähnig P; Jenner P; Marsden C D
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.
Psychopharmacology 1992;109(1-2):49-56.
1991: Löschmann P A; Smith L A; Lange K W; Jaehnig P; Jenner P; Marsden C D
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets.
Psychopharmacology 1991;105(3):303-9.

Sign-in to see more